Cemiplimab for Merkel Cell Carcinoma
Trial Summary
What is the purpose of this trial?
The goal of this clinical research study is to determine if Cemiplimab-rwlc (called Cemiplimab in this document) given prior to tumor resection surgery is safe and effective in treating (1) Merkel Cell Carcinoma or (2) Cutaneous Squamous Cell Carcinoma (CSCC).
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, if you are on immunosuppressive therapy or have recently received certain cancer treatments, you may need to stop those before participating. It's best to discuss your specific medications with the trial team.
What data supports the effectiveness of the drug Cemiplimab for treating Merkel Cell Carcinoma?
Research shows that immune checkpoint inhibitors, like Cemiplimab, are standard treatments for advanced Merkel Cell Carcinoma, with 43% of patients experiencing a positive response to immunotherapy. This suggests that Cemiplimab, as an immune checkpoint inhibitor, may be effective for some patients with this type of cancer.12345
Is cemiplimab generally safe for human use?
Cemiplimab has been shown to have acceptable safety in clinical trials for advanced cutaneous squamous cell carcinoma, with low rates of treatment discontinuation and death. Common side effects include fatigue, musculoskeletal pain, and decreased appetite, but it is generally considered safe for use in humans.678910
How does the drug cemiplimab differ from other treatments for Merkel cell carcinoma?
Eligibility Criteria
This trial is for adults with newly diagnosed or recurrent Stage I-II Merkel Cell Carcinoma, or advanced Cutaneous Squamous Cell Carcinoma. Candidates must be fit for surgery, have an ECOG status of 0-2, and agree to use effective contraception if applicable. Excluded are those with other recent cancers, certain immune conditions, severe allergies to cemiplimab components, and uncontrolled infections.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Neoadjuvant Treatment
Participants receive cemiplimab 350 mg IV at least 3 weeks prior to surgical resection
Post-Surgery Treatment
Participants continue to receive 350 mg cemiplimab every 3 weeks for up to 8 additional doses
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Cemiplimab-Rwlc (PD-1 Inhibitor)